| Title |
Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity
|
|---|---|
| Published in |
International Journal of Nanomedicine, April 2015
|
| DOI | 10.2147/ijn.s75962 |
| Pubmed ID | |
| Authors |
Gregory Marslin, Ann Mary Revina, Vinoth Kumar Megraj Khandelwal, Krishnamoorthy Balakumar, Jose Prakash, Gregory Franklin, Caroline J Sheeba |
| Abstract |
Clinical effectiveness of imatinib mesylate in cancer treatment is compromised by its off-target cardiotoxicity. In the present study, we have developed physically stable imatinib mesylate-loaded poly(lactide-co-glycolide) nanoparticles (INPs) that could sustainably release the drug, and studied its efficacy by in vitro anticancer and in vivo cardiotoxicity assays. MTT (methylthiazolyldiphenyl-tetrazolium bromide) assay revealed that INPs are more cytotoxic to MCF-7 breast cancer cells compared to the equivalent concentration of free imatinib mesylate. Wistar rats orally administered with 50 mg/kg INPs for 28 days showed no significant cardiotoxicity or associated changes. Whereas, increased alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels, and reduced white blood cell, red blood cell, and hemoglobin content were observed in the animals administered with free drug. While the histological sections from hearts of animals that received INPs did not show any significant cardiotoxic symptoms, loss of normal architecture and increased cytoplasmic vacuolization were observed in the heart sections of animals administered with free imatinib mesylate. Based on these results, we conclude that nano-encapsulation of imatinib mesylate increases its efficacy against cancer cells, with almost no cardiotoxicity. |
Mendeley readers
The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 2% |
| Unknown | 55 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 25% |
| Student > Master | 7 | 13% |
| Researcher | 5 | 9% |
| Student > Bachelor | 4 | 7% |
| Professor > Associate Professor | 3 | 5% |
| Other | 7 | 13% |
| Unknown | 16 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 27% |
| Medicine and Dentistry | 4 | 7% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Chemistry | 3 | 5% |
| Agricultural and Biological Sciences | 3 | 5% |
| Other | 7 | 13% |
| Unknown | 21 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 May 2015.
All research outputs
#22,759,452
of 25,374,647 outputs
Outputs from International Journal of Nanomedicine
#3,598
of 4,123 outputs
Outputs of similar age
#240,606
of 279,166 outputs
Outputs of similar age from International Journal of Nanomedicine
#74
of 85 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,123 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,166 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 85 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.